Local versus central laboratory discrepancies in the determination of triple-negative breast cancer (TNBC) status in a large phase III (CIBOMA/2004-01/GEICAM/2003-11) trial assessing adjuvant capecitabine (C) maintenance therapy after standard chemotherapy (CT) in early breast cancer (EBC) patients (pts).
M. Ruiz-Borrego
Other Remuneration - Roche
C. H. Barrios
No relevant relationships to disclose
A. Lluch
Honoraria - Roche
Other Remuneration - Roche
J. Bines
No relevant relationships to disclose
J. G. M. Segalla
No relevant relationships to disclose
A. Ruiz
Honoraria - Roche
L. Torrecillas
No relevant relationships to disclose
A. Llombart-Cussac
Honoraria - Roche
R. Torres
No relevant relationships to disclose
J. Á. Garcia Saenz
No relevant relationships to disclose
J. A. Lopez Garcia-Asenjo
No relevant relationships to disclose
H. L. Gomez
No relevant relationships to disclose
J. R. De la Haba
Consultant or Advisory Role - Roche
Honoraria - Roche
S. Reyes
No relevant relationships to disclose
E. Martinez
No relevant relationships to disclose
J. M. Baena
No relevant relationships to disclose
L. Perez-Michell
No relevant relationships to disclose
A. Rodriguez-Lescure
Research Funding - Roche
A. Anton
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Other Remuneration - Roche
M. Martin
Other Remuneration - Roche